2023 SV Therapeutics Impact & ESG Report (click to view)
At SV, we invest in biotech companies developing innovative therapeutics based on novel science to address critical unmet medical needs. These companies have the potential to change the practice of medicine and deliver a meaningful positive impact to patients whilst generating attractive returns for our investors.
We have been doing this for over 30 years. SV therefore has an extensive track record of building high value, successful biotech companies with the potential to take transformational new medicines from discovery to market.
As a leading life sciences investor with $2.0bn under management, we are aware of our potential impact and therefore seek to ensure our portfolio companies adopt good ESG practices and are good corporate citizens.
SV’s ESG-focussed activities are carried out with the intention of enabling our portfolio companies to meet their full potential and therefore drive the best chance of delivering meaningful therapeutics to patients and returns for investors.
For the past three decades, we have recognised the importance of ESG, particularly good governance and social management in our portfolio companies. This is often via a board seat which provides us with a valuable vantage point to support our companies.
More recently, SV has introduced a specialised framework to track the progress of our portfolio companies against key value driving governance and social metrics as well as environmental metrics. We are thrilled to report on the ongoing progress made by our portfolio against these.
This report provides a snapshot of the potential impact we seek to deliver. We are extremely proud to be supporting the progression of our companies and delighted to share this update with you.
Kate Bingham & Nikola Trbovic on behalf of the SV Therapeutics Team
View the article
